TP53 and cancer: Nonetheless, the curcumin compound was able to downregulate mutp53 (in mutp53-carrying cancer cell lines) through HSP90 downregulation and induce a certain degree of cell death, and such outcome was improved by NRF2 silencing [13]; in addition, the curcumin compound was able to activate wtp53 (in wild-type p53-carrying cancer cell lines), following DNA damage, and even in this case, the cell death outcome was increased after NRF2 silencing [13], suggesting that NRF2 silencing might improve the p53 response in anticancer therapies.